DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “hold” rating restated by research analysts at Robert W. Baird in a note issued to investors on Sunday. They presently have a $79.00 price objective on the medical device company’s stock. Robert W. Baird’s price target points to a potential upside of 8.03% from the stock’s current price.
Several other equities research analysts have also issued reports on DXCM. Piper Jaffray Companies reissued an “overweight” rating and set a $78.00 price target on shares of DexCom in a research report on Monday, May 22nd. Canaccord Genuity reissued a “buy” rating and set a $90.00 price target on shares of DexCom in a research report on Wednesday, June 7th. BidaskClub raised DexCom from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. BMO Capital Markets reissued a “buy” rating and set a $105.00 price target on shares of DexCom in a research report on Thursday, July 13th. Finally, Cowen and Company reissued a “buy” rating and set a $90.00 price target on shares of DexCom in a research report on Friday, July 14th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $87.64.
DexCom (NASDAQ:DXCM) opened at 73.13 on Friday. The firm has a 50-day moving average of $71.97 and a 200 day moving average of $74.23. DexCom has a 52 week low of $57.68 and a 52 week high of $95.40. The stock’s market capitalization is $6.33 billion.
DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. During the same period in the prior year, the company posted ($0.24) EPS. DexCom’s quarterly revenue was up 24.3% on a year-over-year basis. On average, analysts anticipate that DexCom will post ($0.77) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “DexCom, Inc. (DXCM) Rating Reiterated by Robert W. Baird” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://sportsperspectives.com/2017/09/12/dexcom-inc-dxcm-rating-reiterated-by-robert-w-baird.html.
In related news, EVP Andrew K. Balo sold 3,200 shares of the firm’s stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $71.55, for a total transaction of $228,960.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total value of $123,050.10. Following the transaction, the executive vice president now directly owns 72,395 shares of the company’s stock, valued at approximately $5,448,447.70. The disclosure for this sale can be found here. In the last three months, insiders sold 22,979 shares of company stock valued at $1,646,805. Company insiders own 1.70% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Advisor Group Inc. lifted its holdings in shares of DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after purchasing an additional 837 shares during the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of DexCom during the first quarter valued at $164,000. Daiwa Securities Group Inc. lifted its holdings in shares of DexCom by 475.0% during the first quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock valued at $195,000 after purchasing an additional 1,900 shares during the last quarter. Accredited Investors Inc. purchased a new stake in shares of DexCom during the first quarter valued at $201,000. Finally, Brighton Jones LLC purchased a new stake in shares of DexCom during the first quarter valued at $204,000.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.